Hologic's (HOLX) performance in the third quarter of fiscal 2024 marks a return to growth, along with revenues and earnings beating estimates. Read on to find out what else the stock holds.

Examine the evolution of Hologic's (HOLX) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

Zacks.com users have recently been watching Hologic (HOLX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Stephen MacMillan, Hologic CEO, joins 'Money Movers' to discuss the company's earnings, how the company is encouraging women to get health screenings, and more.

Hologic (HOLX) delivers strong performances across all its franchises in the third quarter of fiscal 2024.

Hologic, Inc. HOLX reported upbeat earnings for its third quarter, but issued soft guidance on Monday.

Hologic, Inc. (NASDAQ:HOLX ) Q3 2024 Earnings Conference Call July 29, 2024 4:30 AM ET Company Participants Ryan Simon - VP, IR Stephen MacMillan - Chairman, President & CEO Essex Mitchell - COO Karleen Oberton - CFO Conference Call Participants Patrick Donnelly - Citi Tejas Savant - Morgan Stanley Jack Meehan - Nephron Research Vijay Kumar - Evercore Anthony Petrone - Mizuho Securities Michael Matson - Needham & Company Casey Woodring - JPMorgan Michael Ryskin - Bank of America Navann Ty - BNP Paribas Ryan Zimmerman - BTIG Mason Carrico - Stephens Andrew Cooper - Raymond James Puneet Souda - Leerink Partners Operator Good afternoon, and welcome to the Hologic's Third Quarter Fiscal 2024 Earnings Conference Call. My name is Cynthia, and I am your operator for today's call.

The headline numbers for Hologic (HOLX) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Medical technology company Hologic reported a higher third-quarter profit on Monday, driven by strong demand for its diagnostics and breast health products, but forecast revenue for the current quarter that fell short of Wall Street estimates.

Hologic (HOLX) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $0.93 per share a year ago.

Investors interested in stocks from the Medical - Instruments sector have probably already heard of Hologic (HOLX) and SONOVA HOLDING (SONVY). But which of these two stocks offers value investors a better bang for their buck right now?